A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
HIV Infections

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, Antiviral Agents, Zidovudine, HIV Protease Inhibitors, Lamivudine, Indinavir
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed for all patients: Standard prophylaxis for opportunistic infections. Continuation of treatment for opportunistic infection. Allowed for open-label study patients: Rifampin. Patients must have: HIV positivity. CD4 count <= 50 cells/mm3. More than 6 months of prior AZT (blinded study only). NOTE: Patients on the open-label study must have AZT intolerance or have < 6 months of prior AZT. Prior Medication: Required for blinded study patients: > 6 months of prior AZT. Required for open-label study patients: < 6 months of prior AZT. Allowed for open-label study patients: Prior 3TC. Exclusion Criteria Concurrent Medication: Excluded in all patients: Immunosuppressants. Excluded in blinded study patients: AZT, ddI, ddC, or d4T. Rifampin. Excluded in open-label study patients: 3TC. Prior Medication: Excluded in all patients: Prior protease inhibitors. Investigational agents and immunomodulators within 30 days prior to study entry. Immunosuppressants within 2 weeks prior to study entry. Excluded in blinded study patients: Any prior 3TC. AZT, ddI, ddC, or d4T within 2 weeks prior to study entry. Excluded in open-label study patients: 3TC within 30 days prior to study entry.
Sites / Locations
- Merck & Co Inc